Skip to main content
Canna~Fangled Abstracts

Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer’s disease symptoms: a case report

By July 12, 2022July 13th, 2022No Comments

. 2022 Jul 12;16(1):277.

doi: 10.1186/s13256-022-03457-w.

Ana Carolina Ruver-Martins 1, Maíra Assunção Bicca 2, Fabiano Soares de Araujo 3, Beatriz Helena Lameiro de Noronha Sales Maia 3, Fabrício Alano Pamplona 1, Elton Gomes da Silva 1, Francisney Pinto Nascimento 4
Affiliations 

Abstract

Background: Cannabinoid-based therapy has been shown to be promising and is emerging as crucial for the treatment of cognitive deficits, mental illnesses, and many diseases considered incurable. There is a need to find an appropriate therapy for Alzheimer’s disease, and cannabinoid-based therapy appears to be a feasible possibility.

Case presentation: This report addresses the beneficial effect of cannabinoids in microdoses on improving memory and brain functions of a patient with mild-stage Alzheimer’s disease. The patient is a 75-year-old white man presenting with main symptoms of memory deficit, spatial and temporal disorientation, and limited daily activity. The experimental therapeutic intervention was carried out for 22 months with microdoses of a cannabis extract containing cannabinoids. Clinical evaluations using Mini-Mental State Examination and Alzheimer’s Disease Assessment Scale-Cognitive Subscale were performed.

Conclusions: Here we provide original evidence that cannabinoid microdosing could be effective as an Alzheimer’s disease treatment while preventing major side effects. This is an important step toward dissociating cannabinoids’ health-improving effects from potential narcotic-related limitations.

Keywords: AD treatment, Alzheimer’s disease, Cannabinoid extract, Cannabinoids, Case report, Microdosing

References

    1. Alzheimer’s Association. Alzheimer’s Disease: facts and figures. Alzheimers Dement. 2018;14(3):367–429.
    1. Pinto RS, et al. Doença de Alzheimer: Abordagem farmacoterapêutica. Bol Inf Geum. 2015;6(1):16–25.
    1. Mucke L. Alzheimer’s disease. Nature. 2009;461(7266):895–7. – PubMed
    1. Cline EN, et al. The amyloid-β oligomer hypothesis: beginning of the third decade. J Alzheimer’s Dis. 2018;64(s1):S567-610.
    1. Iuvone T, et al. Neuroprotective effect of cannabidiol, a non-psychoactive component from cannabis sativa, on β-amyloid-induced toxicity in PC12 cells. J Neurochem. 2004;89(1):134–41. – PubMed

Leave a Reply